Grant Number:	5R35CA253187-03 Interpret this number
Primary Investigator:	Couch, Fergus
Organization:	Mayo Clinic Rochester
Project Title:	Resolving the Cancer Relevance of Predisposition Gene Mutations
Fiscal Year:	2022

Breast cancer has a strong heritable component with approximately 15% of patients exhibiting a family history of the disease. My group recently established that inherited variants in 12 genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, and TP53) predispose to breast cancer (1, 2), that variants in all 12 genes increase risks of breast cancer in minority populations (3), and that variants in certain genes predispose only to estrogen receptor (ER) positive (ATM and CHEK2) or ER negative and triple negative breast cancer (TNBC) (BARD1, RAD51C and RAD51D) (4-6). Despite these major advances, clinical application of the information is still lacking. In addition, up to 50% of the familial risk of breast cancer remains unexplained. Under this award we plan to address clinically relevant issues, including improved application of genetic testing results for risk management of patients and improved selection of breast cancer therapy. In addition, we aim to identify new breast cancer predisposition genes that account for the missing heritability. The proposed studies are unified under a theme of advancing understanding of predisposition genetics. The studies are as follows: A. Age-specific and population-specific cancer risk assessment for predisposition gene variants. Results from hereditary multigene panel testing has limited clinical utility because only lifetime risk estimates of cancer by age 80 are available. Here we will estimate 5 and 10-year risks of breast cancer, so that patients can make decisions about medical management. In addition, we have evidence that specific genes have much higher penetrance in African Americans. We will determine the penetrance of predisposition gene variants using a large African American cohort study in order to modify risk management guidelines for this population. B. Functional characterization of predisposition gene variants. Variants of uncertain significance (VUS) identified by genetic testing remain a major problem for individuals receiving clinical genetic testing. We aim to combine high-throughput functional analysis of VUS in ATM, BRCA2 and PALB2 genes with genetic data from families in integrated models to determine the clinical relevance of many VUS alterations. C. Therapeutic response for breast cancer predisposition genes. The responsiveness of breast tumors associated with predisposition gene variants to standard or targeted therapy is only known for BRCA1 and BRCA2 mutation carriers. Here we aim to identify all patients with pathogenic variants in the commonly mutated BRCA1, BRCA2, PALB2, ATM and CHEK2 genes from a series of neo-adjuvant, adjuvant and metastatic breast cancer clinical trials and to assess response to therapy and outcome. D. Identification of novel breast cancer predisposition alleles. The common and rare risk alleles for breast cancer account for only 50% of the familial risk in the population. In an effort to identify the missing heritability we will collaborate with Regeneron Inc. through our SIMPLEXO consortium to identify common and rare alleles associated with breast cancer risk in 45,000 breast cancer patients.




Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
Authors: Chen F. , Park S.L. , Wilkens L.R. , Wan P. , Hart S.N. , Hu C. , Yadav S. , Couch F.J. , Conti D.V. , de Smith A.J. , et al. .
Source: Cancer research, 2022-09-16; 82(18), p. 3201-3208.
PMID: 35834270
Related Citations

Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
Authors: Hu C. , Susswein L.R. , Roberts M.E. , Yang H. , Marshall M.L. , Hiraki S. , Berkofsky-Fessler W. , Gupta S. , Shen W. , Dunn C.A. , et al. .
Source: Clinical cancer research : an official journal of the American Association for Cancer Research, 2022-09-01; 28(17), p. 3742-3751.
PMID: 35736817
Related Citations

An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance.
Authors: Iversen E.S. , Lipton G. , Hart S.N. , Lee K.Y. , Hu C. , Polley E.C. , Pesaran T. , Yussuf A. , LaDuca H. , Chao E. , et al. .
Source: NPJ genomic medicine, 2022-06-03; 7(1), p. 35.
EPub date: 2022-06-03.
PMID: 35665744
Related Citations

Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.
Authors: Cosgrove N. , Varešlija D. , Keelan S. , Elangovan A. , Atkinson J.M. , Cocchiglia S. , Bane F.T. , Singh V. , Furney S. , Hu C. , et al. .
Source: Nature communications, 2022-01-26; 13(1), p. 514.
EPub date: 2022-01-26.
PMID: 35082299
Related Citations

Rare germline copy number variants (CNVs) and breast cancer risk.
Authors: Dennis J. , Tyrer J.P. , Walker L.C. , Michailidou K. , Dorling L. , Bolla M.K. , Wang Q. , Ahearn T.U. , Andrulis I.L. , Anton-Culver H. , et al. .
Source: Communications biology, 2022-01-18; 5(1), p. 65.
EPub date: 2022-01-18.
PMID: 35042965
Related Citations

Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
Authors: Yadav S. , Hu C. , Nathanson K.L. , Weitzel J.N. , Goldgar D.E. , Kraft P. , Gnanaolivu R.D. , Na J. , Huang H. , Boddicker N.J. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021-12-10; 39(35), p. 3918-3926.
EPub date: 2021-10-21.
PMID: 34672684
Related Citations

Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Authors: Boddicker N.J. , Hu C. , Weitzel J.N. , Kraft P. , Nathanson K.L. , Goldgar D.E. , Na J. , Huang H. , Gnanaolivu R.D. , Larson N. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021-11-01; 39(31), p. 3430-3440.
EPub date: 2021-07-22.
PMID: 34292776
Related Citations

Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.
Authors: Escala-Garcia M. , Canisius S. , Keeman R. , Beesley J. , Anton-Culver H. , Arndt V. , Augustinsson A. , Becher H. , Beckmann M.W. , Behrens S. , et al. .
Source: Scientific reports, 2021-10-05; 11(1), p. 19787.
EPub date: 2021-10-05.
PMID: 34611289
Related Citations

Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer.
Authors: Yadav S. , LaDuca H. , Polley E.C. , Hu C. , Niguidula N. , Shimelis H. , Lilyquist J. , Na J. , Lee K.Y. , Gutierrez S. , et al. .
Source: Journal of the National Cancer Institute, 2021-10-01; 113(10), p. 1429-1433.
PMID: 33146377
Related Citations

Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
Authors: Gao C. , Polley E.C. , Hart S.N. , Huang H. , Hu C. , Gnanaolivu R. , Lilyquist J. , Boddicker N.J. , Na J. , Ambrosone C.B. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021-08-10; 39(23), p. 2564-2573.
EPub date: 2021-06-08.
PMID: 34101481
Related Citations

Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States.
Authors: Domchek S.M. , Yao S. , Chen F. , Hu C. , Hart S.N. , Goldgar D.E. , Nathanson K.L. , Ambrosone C.B. , Haiman C.A. , Couch F.J. , et al. .
Source: JAMA oncology, 2021-07-01; 7(7), p. 1045-1050.
PMID: 34042955
Related Citations

Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
Authors: Fasching P.A. , Yadav S. , Hu C. , Wunderle M. , Häberle L. , Hart S.N. , Rübner M. , Polley E.C. , Lee K.Y. , Gnanaolivu R.D. , et al. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021-05-20; 39(15), p. 1619-1630.
EPub date: 2021-03-29.
PMID: 33780288
Related Citations

Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance.
Authors: Richardson M.E. , Hu C. , Lee K.Y. , LaDuca H. , Fulk K. , Durda K.M. , Deckman A.M. , Goldgar D.E. , Monteiro A.N.A. , Gnanaolivu R. , et al. .
Source: American journal of human genetics, 2021-03-04; 108(3), p. 458-468.
EPub date: 2021-02-19.
PMID: 33609447
Related Citations

A Population-Based Study of Genes Previously Implicated in Breast Cancer.
Authors: Hu C. , Hart S.N. , Gnanaolivu R. , Huang H. , Lee K.Y. , Na J. , Gao C. , Lilyquist J. , Yadav S. , Boddicker N.J. , et al. .
Source: The New England journal of medicine, 2021-02-04; 384(5), p. 440-451.
EPub date: 2021-01-20.
PMID: 33471974
Related Citations